When cure becomes an illness—abuse of addictive prescription medicines

Jakovljević, Mihajlo; Lazarević, Marija; Jurišević, Milena; Jovanovic, Mirjana

doi:10.3389/fphar.2015.00193

Cited by 6 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alcohol abuse is a health problem that significantly contributes to the global disability (liver-diseases, cardiovascular diseases, traffic accidents, fights, murders, suicides; Jakovljevic et al, 2015a ), but also it is an economic problem (absenteeism, unemployment, reduced productivity, long-term treatment) (Jakovljevic et al, 2011 ). Psychoactive substances present a great challenge of public health issue worldwide particularly regarding to the social vulnerable population of adolescents (Jakovljevic et al, 2015b ).…”

Section: Comparison With Published Evidencementioning

confidence: 99%

Socioeconomic Factors Associated with Psychoactive Substance Abuse by Adolescents in Serbia

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Comparison With Published Evidencementioning

confidence: 99%

Socioeconomic Factors Associated with Psychoactive Substance Abuse by Adolescents in Serbia

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…The scale of the impact of the misuse of such pharmaceuticals worldwide remains, however, unknown due to a lack of epidemiological data. Nevertheless, a high prevalence of non-medical prescription drug use has been reported in countries such as the US, Canada, Australia, and some European countries (5, 6). …”

Section: Introductionmentioning

confidence: 99%

Methodological Considerations in Social Cost Studies of Addictive Substances: A Systematic Literature Review

Verhaeghe

Lievens

Annemans

et al. 2017

Front. Public Health

View full text Add to dashboard Cite

BackgroundAlcohol, tobacco, illicit drugs, and psychoactive pharmaceuticals’ use is associated with a higher likelihood of developing several diseases and injuries and, as a consequence, considerable health-care expenditures. There is yet a lack of consistent methodologies to estimate the economic impact of addictive substances to society. The aim was to assess the methodological approaches applied in social cost studies estimating the economic impact of alcohol, tobacco, illicit drugs, and psychoactive pharmaceuticals.MethodsA systematic literature review through the electronic databases, Medline (PubMed) and Web of Science, was performed. Studies in English published from 1997 examining the social costs of the addictive substances alcohol, tobacco, illicit drugs, and psychoactive pharmaceuticals were eligible for inclusion.ResultsTwelve social cost studies met the inclusion criteria. In all studies, the direct and indirect costs were measured, but the intangible costs were seldom taken into account. A wide variety in cost items included across studies was observed. Sensitivity analyses to address the uncertainty around certain cost estimates were conducted in eight studies considered in the review.ConclusionDifferences in cost items included in cost-of-illness studies limit the comparison across studies. It is clear that it is difficult to deal with all consequences of substance use in cost-of-illness studies. Future social cost studies should be based on sound methodological principles in order to result in more reliable cost estimates of the economic burden of substance use.

show abstract

“…Finally, the results from our findings were based on a nationally representative sample of the civilian, non-institutionalized U.S. population, which may limit the generalizability to other countries. However, other nations have reported similar experiences with the opioid crises and may find these findings useful [ 38 – 41 ].…”

Section: Discussionmentioning

confidence: 99%

Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017

Bounthavong

Suh

et al. 2021

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Background Previous reports on healthcare costs and expenditures associated with populations prescribed an opioid primarily focused on populations who chronically use opioids or have opioid use disorder. However, studies that characterize the healthcare and expenditures costs among the wider number of people prescribed opioids in a nationally representative population are unavailable. We sought to characterize the healthcare costs and expenditures associated with a population prescribed an opioid in the U.S. from 2008 to 2017. Methods A serial cross-sectional design was used to compare the economic burden of adult household respondents who were prescribed and not prescribed an opioid using pooled data from the Medical Expenditure Panel Survey (MEPS) between 2008 and 2017. Respondents with an opioid prescription were matched to respondents without an opioid prescription using propensity score match methods with survey weights. Two-part generalized linear models were used to estimate the survey-weighted annual healthcare expenditures and resource utilization adjusting for multiple covariates. Additionally, 10-year trend comparisons between the groups were performed. Costs were adjusted to 2019 US dollars. Results There was a weighted total of 31,696,671 respondents with an opioid and 31,536,639 respondents without an opioid after propensity score matching. The sample had a mean (SD) age of 50.63 years (18.03), 58.9% females, and 81.6% Whites. Total annual economic burden among RPOs was $524 billion. Annual total expenditures per respondent with and without an opioid were $16,542 and $7067, respectively (P < 0.001). Similarly, adjusted prescription, outpatient, emergency department, and inpatient expenditures were significantly higher for respondents with an opioid compared to respondents without an opioid. Average annual increases in expenditures were significantly greater among respondents with an opioid compared to respondents without an opioid for total (+$185; 95% CI: $37–$334) and prescription (+$78; 95% CI: $28–$128) expenditures. There were no differences in the average annual trends for outpatient, emergency department, and inpatient expenditures between respondents with and without an opioid. Conclusions Respondents with an opioid prescription had higher healthcare expenditures and resource utilization compared to respondents without an opioid prescription from 2008 to 2017. Specifically, significant annual increases were observed for total and prescription expenditures. Additionally, 10-year trends in total and prescription expenditures were higher among respondents with an opioid than respondents without an opioid.

show abstract

When cure becomes an illness—abuse of addictive prescription medicines

Cited by 6 publications

References 28 publications

Socioeconomic Factors Associated with Psychoactive Substance Abuse by Adolescents in Serbia

Socioeconomic Factors Associated with Psychoactive Substance Abuse by Adolescents in Serbia

Methodological Considerations in Social Cost Studies of Addictive Substances: A Systematic Literature Review

Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017

Contact Info

Product

Resources

About